



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

N4bp2l1 siRNA (m): sc-149779

BACKGROUND

Comprising nearly 4% of human DNA, chromosome 13 contains around 114 million base pairs and 400 genes. Key tumor suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. The gene SLITRK1, which is associated with Tourette syndrome, is on chromosome 13. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections.

REFERENCES

1. Dunham, A., Matthews, L.H., Burton, J., Ashurst, J.L., Howe, K.L., Ashcroft, K.J., Beare, D.M., Burford, D.C., Hunt, S.E., Griffiths-Jones, S., Jones, M.C., Keenan, S.J., Oliver, K., et al. 2004. The DNA sequence and analysis of human chromosome 13. *Nature* 428: 522-528.
2. Deng, H., Le, W.D., Xie, W.J. and Jankovic, J. 2006. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. *Acta Neurol. Scand.* 114: 400-402.
3. Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. *Oncogene* 25: 5220-5227.
4. Grados, M.A. and Walkup, J.T. 2006. A new gene for Tourette's syndrome: a window into causal mechanisms? *Trends Genet.* 22: 291-293.
5. Bugge, M., Collins, A., Hertz, J.M., Eiberg, H., Lundsteen, C., Brandt, C.A., Bak, M., Hansen, C., Delozier, C.D., Lespinasse, J., Tranebjaerg, L., Hahneemann, J.M., Rasmussen, K., Bruun-Petersen, G., Duprez, L., et al. 2007. Non-disjunction of chromosome 13. *Hum. Mol. Genet.* 16: 2004-2010.
6. Hsu, H.F. and Hou, J.W. 2007. Variable expressivity in Patau syndrome is not all related to trisomy 13 mosaicism. *Am. J. Med. Genet. A* 143: 1739-1748.
7. Hall, H.E., Chan, E.R., Collins, A., Judis, L., Shirley, S., Surti, U., Hoffner, L., Cockwell, A.E., Jacobs, P.A. and Hassold, T.J. 2007. The origin of trisomy 13. *Am. J. Med. Genet. A* 143: 2242-2248.
8. Hassler, M., Singh, S., Yue, W.W., Luczynski, M., Lakbir, R., Bader, T., Sanchez-Sanchez, F., Pearl, L.H. and Mitnacht, S. 2007. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction and holoprotein architecture. *Mol. Cell* 28: 371-385.
9. Thorslund, T. and West, S.C. 2007. BRCA2: a universal recombinase regulator. *Oncogene* 26: 7720-7730.

CHROMOSOMAL LOCATION

Genetic locus: N4bp2l1 (mouse) mapping to 5 G3.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

N4bp2l1 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see N4bp2l1 shRNA Plasmid (m): sc-149779-SH and N4bp2l1 shRNA (m) Lentiviral Particles: sc-149779-V as alternate gene silencing products.

For independent verification of N4bp2l1 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149779A, sc-149779B and sc-149779C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

N4bp2l1 siRNA (m) is recommended for the inhibition of N4bp2l1 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor N4bp2l1 gene expression knockdown using RT-PCR Primer: N4bp2l1 (m)-PR: sc-149779-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.